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Abstract
This study presents the development and application of protein lysate microarray (LMA)
technology for verification of presence and quantification of human tissue samples for protein
biomarkers. Sub-picogram range sensitivity has been achieved on LMA using a non-enzymatic
protein detection methodology. Results from a set of quality control experiments are presented
and demonstrate the high sensitivity and reproducibility of the LMA methodology. The optimized
LMA methodology has been applied for verification of the presence and quantification of disease
markers for atherosclerosis. LMA were used to measure lipoprotein [a] and apolipoprotein B100
in 52 carotid endarterectomy samples. The data generated by LMA were validated by ELISA using
the same protein lysates. The correlations of protein amounts estimated by LMA and ELISA were
highly significant, with r2 ≥ 0.98 (p ≤ 0.001) for lipoprotein [a] and with r2 ≥ 0.94 (p ≤ 0.001) for
apolipoprotein B100. This is the first report to compare data generated using proteins microarrays
with ELISA, a standard technology for the verification of the presence of protein biomarkers. The
sensitivity, reproducibility, and high-throughput quality of LMA technology make it a potentially
powerful technology for profiling disease specific protein markers in clinical samples.
Background
Current methodologies used for protein biomarker stud-
ies include i) 2-dimensional polyacrylamide gel electro-
phoresis [2D-PAGE; 1–4]; ii) mass spectrometry [MS; 5–
6]; and iii) immunological assays such as enzyme-linked
immunosorbent assay and radio-immuno assay [ELISA
and RIA; 7–9]. While they are widely used for discovery of
protein biomarkers, MS and 2D-PAGE methodologies
have been used for the verification of the presence of pre-
determined protein biomarkers in few studies. Immuno-
logical assays such as ELISA and RIA are most commonly
used for the verification of the presence of pre-determined
protein biomarkers [7-9]. However, ELISA and RIA are not
readily applicable for detection of known disease markers
from very small amounts of starting materials, like lysates
from cells obtained from clinical samples. A typical test
requires up to micrograms of starting samples that are dif-
ficult to obtain in most cases. Further, these techniques
are not easily adaptable to high throughput applications
Published: 10 November 2005
Proteome Science 2005, 3:9 doi:10.1186/1477-5956-3-9
Received: 25 August 2005
Accepted: 10 November 2005
This article is available from: http://www.proteomesci.com/content/3/1/9
© 2005 Ramaswamy et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
Page 2 of 16
(page number not for citation purposes)
required for handling a large number of samples simulta-
neously.
Microarray-based assays [10-12] provide a solution to
these problems. A microarray is a collection of spatially
addressable probes immobilized on a surface as spots. The
increase in throughput is due to the small spot-size on the
microarray (~150–200 µdiameter) that allows for a large
number of spots per microarray. Thousands of probes
(printed on the microarray surface) can be interrogated
for a specific target (in solution) in a single microarray
experiment. In addition to the high-throughput achieved,
microarray assays are highly sensitive and require
extremely small amounts of samples. The increase in sen-
sitivity in microarray-based methods is due to the minia-
ture format, which leads to an increase in the signal
density [signal intensity/area; 13]. Compared to the micro
titer plate format employed in ELISA, a typical microarray
spot is more than 25 times smaller. This concentrates the
signal density and enhances the signal intensity. The
amount of sample required to saturate a microarray spot
also decreases in proportion to its surface area and hence
typically a few nanograms are sufficient for several micro-
array experiments. Thus, sensitivity comparable to or
exceeding ELISA can be achieved on microarrays using
only a fraction (down to 1/1000th) of the sample size
required for ELISA. The advantage gained by miniaturiza-
tion, high sensitivity, and high throughput makes protein
microarrays a potentially powerful technology for discov-
ery of new markers and detection of known protein mark-
ers [14-20].
In the present study we show the development and appli-
cation of protein lysate microarrays (LMA), also known as
reverse phase arrays [21,22] for interrogating multiple
human samples for disease-specific protein markers in a
single experiment. In LMA, the samples (up to thousands)
are immobilized on the surface of the microarray and a
single antibody for the protein biomarker is used to screen
the samples for its presence. Each antibody on LMA is
used in an independent experiment that is focused on
profiling expression of a specific protein across all sam-
ples printed on the array leading to uniformity of results.
Use of a single antibody also allows for the determination
of differences in protein marker levels in different patient
samples with greater accuracy.
Variations of LMA technology have been used in different
applications in recent years [23,24]. Using lysates pre-
pared from laser capture microdissected human samples,
reverse-phase arrays methodology have been successfully
used to study regulation of pro-survival pathways at the
transition from normal prostate epithelium to intraepi-
thelial neoplasia and into invasive prostate cancer [21].
Madoz-Gurpide and coworkers [25] performed liquid
phase protein separation of extracts prepared from lung
adenocarcinoma A549 cell line and the various fractions
were microarrayed and probed with antibodies against
specific proteins. Nishizuka and coworkers [22] have
recently used reverse-phase arrays to screen compounds
for anticancer activity in a panel containing 60 human
cancer cell lines. LMA have also been used for multiplexed
analysis of proteins where 2 different antibodies were
used for binding on the same arrays for verification of the
presence of 2 different proteins or to determine the phos-
phorylation status of the proteins of interest [26,27].
The signal detection method used in most of the above
studies was an enzymatic tyramide-based reaction that
catalyzes the deposition of multiple dye molecules at the
antibody-binding site. A drawback of this method is the
inability to control the enzymatic reaction of the deposi-
tion of dyes that often results in saturation of the signal
intensities of the microarray spots. In a previous report
[28], we presented the various issues associated with using
a tyramide-based amplification method for signal detec-
tion on microarrays. A biotin-streptavidin based (non-
enzymatic) signal amplification and detection methodol-
ogy used in the LMA experiments presented here over-
comes the signal saturation problems faced with the
enzymatic tyramide-based methodology.
In this report we present the development and validation
of LMA for verification of the presence and quantification
of predetermined protein markers using antibodies tested
for specificity by Western blot analysis. We have per-
formed quality control experiments to evaluate and opti-
mize the LMA methodology. We have applied the
optimized LMA methodology for verification of the pres-
ence and quantification of protein markers from athero-
sclerotic samples. The results were highly correlative with
those obtained by ELISA using the same lysates (with r2 ≥
0.98 (p ≤ <0.001) for lipoprotein [a] and r2 ≥ 0.94 (p ≤
0.001) for apolipoprotein B100), but required much less
amount of samples. This is the first study to show a paral-
lel comparison of protein microarray data with a standard
tool like ELISA, for detection of known protein markers.
Results
We present here the results from experiments performed
to test and validate the LMA technology for verification of
the presence and quantification of specific-protein
biomarker. We chose to use a cell line for the initial qual-
ity control experiments for LMA to facilitate economical
use of the available patient samples. F9, a murine terato-
carcinoma cell line that can be easily cultured was used.
This cell line over expresses tumor suppressor protein p53
[29] and therefore we determined the expression level of
p53 in protein lysates prepared from F9 cells in these LMA
experiments. Lysates prepared from this cell line wereProteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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used to optimize printing and binding steps on LMA. Nor-
mal human plasma samples were also used to show the
reproducibility of the data generated. All together, the
results from the quality control experiments demonstrate
reproducibility of LMA printing, linearity of the different
binding steps and signal detection and sensitivity of the
LMA methodology. Next, we applied the LMA technology
for verification of the presence of and quantification of
specific-protein markers from atherosclerotic tissue sam-
ples and compared the data generated with those from
ELISA experiments.
Reproducibility in LMA printing
One of the major problems in microarray printing is the
spot-to-spot variation introduced due to differences in
amount of material dispensed. To demonstrate the uni-
formity of our dispensing (printing) method, we prepared
Cy3-labeled protein lysates from F9 cells, made serial
dilutions (7 different concentrations) and printed them
on slides. The data set consisted of six arrays with 3 repli-
cates per lysate amount per array, resulting in a total of 18
data points per lysate amount. The plot in figure 1 shows
a correlative increase in the signal intensity with increase
in the printed lysate amount. Table 1 shows a summary of
the statistics (mean, standard deviation (SD) and coeffi-
cient of variance (CV)) of the data generated. We observed
a CV of 2.59–5.47% for the 18 data points per lysate
amount printed, indicating high reproducibility in LMA
printing. Similar data were generated using Cy5-labeled
protein lysates (not shown).
Linearity of the different binding steps on LMA
We used a sandwich assay methodology for signal detec-
tion on LMA. Lysates prepared from samples were printed
on nitrocellulose membrane coated slides and incubated
with a specific antibody against the antigen of interest.
The arrays were incubated with a biotinylated secondary
antibody followed by signal detection using streptavidin
linked to Cy3 (or Cy5) dye. The final signal intensity of
the LMA spots results from a sequential combination of 3
binding events: 1) binding of the primary antibody to the
protein marker in the lysate; 2) binding of the secondary
antibody to the primary antibody; and 3) the binding of
Cy3-labeled streptavidin to the secondary antibody (Fig-
ure 2). To obtain uniform, reproducible and accurate
results it is essential to ascertain that each of these binding
reactions occurs in a linear fashion.
Schematic of the different binding steps on LMA Figure 2
Schematic of the different binding steps on LMA. F9 lysates 
or purified p53 protein, purified primary p53 antibody, bioti-
nylated secondary antibody, and Cy3-labeled streptavidin 
were printed on spots i, ii, iii and iv on the LMA, respectively. 
A diagrammatic representation of the different binding steps 
performed for signal detection on LMA is shown.
Spot i ii iii iv
Step 1
Step 2
Step 3
Protein/lysate
Primary
Antibody
Secondary
Antibody
Dye
Table 1: Summary of data statistics for LMA containing labeled lysates
0.109 0.219 0.438 0.875 1.75 3.5 7.0 (ng)
MEAN 1891.25 3313.75 6152.20 10898.40 18032.50 33889.75 50389.00
SD 76.34 85.92 180.90 444.80 986.24 1197.71 1352.43
CV (%) 4.04 2.59 2.94 4.08 5.47 3.53 2.68
Correlation of signal intensity to lysate amount printed on  LMA Figure 1
Correlation of signal intensity to lysate amount printed on 
LMA. Cy3-labeled F9 lysate amount (0.109 – 7.0 ng) printed 
on LMA was plotted against signal intensity.
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The linearity of each of the binding reactions on the LMA
was determined as follows: LMA with spots containing F9
lysates or purified p53 protein (Figure 2, spot i), purified
primary p53 antibody (Figure 2, spot ii), biotinylated sec-
ondary antibody (Figure 2, spot iii) and Cy3-labeled
streptavidin (Figure 2, spot iv) were printed. In step 1 of
binding, LMA was incubated with the primary p53 anti-
body, in step 2 with biotinylated secondary antibody and
finally with Cy3-labeled streptavidin in step 3. In step 1 of
binding, the primary antibody will bind to the F9 lysate
(that are positive for p53; [29]) and purified p53 protein
(Figure 2, spot i). In step 2, the biotinylated secondary
antibody will bind to the primary antibody now bound to
the F9 lysate and purified p53 protein (Figure 2, spot i),
and to purified primary antibody printed on the surface at
spot 'ii'. In step 3 the Cy3-labeled streptavidin will bind to
secondary antibody generating fluorescent signals at spots
'i', 'ii' and 'iii'. No reactions were expected on spot 'iv'
where Cy3-labeled streptavidin alone was printed.
Each reagent on the array was printed in a serial dilution.
Each dilution of the different reagents was printed in
duplicate on the arrays. Two arrays were processed result-
ing in 4 data-points per concentration per reagent. This
experimental design allows determination of the linearity
of each binding reaction contributing to the final signal,
reproducibility of each reaction and saturation if any, of
the binding reactions. The plot in figure 3 shows that all
the binding steps described above occurred in a linear and
reproducible fashion and did not saturate. Figure 4 shows
a Western Blot where extracts from F9 cells (lane 2) were
probed for detection of p53 by the same antibody that was
used in the LMA experiments. Lysates from bacteria over-
expressing p53 protein were used as a positive control for
p53 (lane 1). These data demonstrate the expression of
p53 protein in F9 cells and the specificity of this antibody
as indicated by the unique p53 band observed on the
Western blot.
Reproducibility of signal detection on LMA
Serial dilutions of normal human plasma samples were
printed onto membrane-coated glass slides. Lysate stocks
used for printing were 0.625, 1.25, 2.5 and 5 µg/µl. The
volume printed per spot by the robot is estimated to be 1
nl (Genomics Solutions, Inc. Irvine, CA). The printed
amounts of lysates in each dilution series were 0.625,
1.25, 2.5 and 5 × 10-9 g (nanograms; ng). Printing buffer
(1X PBS) was used as a negative control. Each concentra-
tion of the plasma sample was printed 24 times per array
and each experiment was performed in duplicate, result-
ing in a total of 48 data points per concentration. The
arrays were incubated with an antibody against β-actin.
Figure 5 (top) shows the two arrays, with serially diluted
samples shown left to right in each row in each of the 4
sub-arrays in the 2 arrays. The printing buffer was spotted
as negative control in the fifth column in each sub-array.
A third array processed as a negative control where no pri-
mary antibody was added to the binding step, showed no
discernable signals (Figure 5 bottom). The signals
observed in this third array were close to background sug-
gesting no binding by the secondary antibody in the
absence of the primary antibody. Figure 6 shows a plot of
correlation between signal intensity and lysate amount
printed. Increase in the amount of printed lysate resulted
in a correlative increase in the signal intensity generated.
Table 2 shows a summary of the statistics of the data gen-
erated. For replicates of each sample spotted on the arrays,
the mean was computed and SD and CV were determined.
We observed a CV of 4.5–5.9% for the 48 data points per
lysate amount printed. These data show that LMA technol-
ogy can potentially be used to reproducibly detect pro-
teins from extremely small amounts of lysate, less than a
nanogram (625 picograms) for detection of β-actin from
human plasma. Figure 7 shows a Western Blot where 2
different human plasma samples were probed for detec-
tion of β-actin by the same antibody that was used in the
LMA experiments. The 40 kD unique band observed on
the Western blot demonstrates the specificity of this anti-
body for β-actin.
Other proteins tested in similar experiments involved
detection of tubulin from human plasma and insulin and
leptin from diabetes serum samples (data not shown). In
all cases, a linear correlation between signal intensity and
lysate amount was observed and the data showed high
reproducibility similar to the dataset presented here.
Sensitivity of LMA
LMA with human plasma lysate amounts ranging from 6
× 10-12g (6 picograms; 6 pg) to 6 × 10-15g (6 femtograms;
6 fg) were printed and probed for β-actin. Two arrays con-
taining 24 replicates of each lysate amount were used for
the experiment resulting in a total of 48 data points per
concentration. Figure 8 shows the scanned images of the
Table 2: Summary of data statistics for LMA where printed lysate amount ranged from 0.625 to 5 ng.
1X PBS 0.625 1.25 2.5 5.0 (ng)
MEAN 396.83 28992.14 32682.63 33619.77 34140.00
SD 27.67 1373.84 1486.66 1683.11 2013.82
CV (%) 6.97 4.74 4.55 5.01 5.90Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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2 arrays each with 4 sub-arrays. Serially diluted samples
are shown left to right in each row in each of the 4 sub-
arrays. The printing buffer was spotted as negative control
in the fifth column in each sub-array. Figure 9 shows a
plot of correlation between signal intensity and lysate
amount. Summary of the data statistics is shown in Table
3. The data show that the mean signal intensity for lysate
amounts lower than 0.6 pg was close to those generated
by the printing buffer (1 × PBS in Figure 9), indicating
these lysate amounts were not optimal for detection of β-
actin from these samples using LMA. At lysate amounts,
0.6 and 6.66 pg the mean signal intensity was several fold
higher (7-fold higher at 0.6 pg and 25-fold higher at 6.66
pg) than background and the data were reproducible with
a CV on the order of 3.3–4.8% (Figure 9 and Table 3).
These data show that β-actin can be reproducibility
detected from less than a picogram (600 femtograms) of
printed human plasma sample.
Application of LMA: Verification of atherosclerotic protein 
biomarkers
In the series of experiments described here, the LMA tech-
nology was used to detect apolipoprotein [a] (apo [a])
and apolipoprotein B100 (Apo B) in samples from
atherosclerotic patients. Apo [a] is contained exclusively
in Lp [a] (lipoprotein [a]; 30–31), whereas Apo B is
present in Lp [a], LDL (low density lipoprotein) and VLDL
(very low-density lipoprotein; 32). Lp [a] is a plasma lipo-
Linearity of different binding steps on LMA Figure 3
Linearity of different binding steps on LMA. LMA containing serially diluted F9 protein lysates (0.055, 0.11, 0.23, 0.46, 0.92, 
1.84, 3.68 and 7.36 ng), purified p53 protein (1.5, 3, 6, 12, 24, 48, 96 and 192 pg), purified primary antibody (1.5, 3, 6, 12, 24, 48, 
96 and 192 pg), biotinylated secondary antibody (11.5, 23, 46, 92, 184, 368, 736 and 1472 pg) and Cy3-labeled streptavidin 
(1.95, 3.9, 7.8, 15.6, 31.2, 62.4, 124.8 and 249.6 ng) were printed. Arrays were probed with p53 antibody followed by binding 
and labeling steps as described in the Methods. Log transformed (base 2) spotted lysate amount was plotted against log trans-
formed (base 2) signal intensity.
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protein whose plasma concentration has been highly cor-
related with cardiovascular disease (e.g. coronary stenosis
determined by quantitative angiography; 30–31). Further-
more, the plasma Lp [a] concentrations are significantly
associated with tissue Lp [a] levels in resected bypass vein
grafts and aortic aneurisms [30,31]. These observations
suggest that Lp [a] may play a significant role in athero-
sclerosis occurring in other vascular beds such as the
carotid arteries. Hence it was quite reasonable to measure
Lp [a] in carotid plaques obtained by endarterectomy.
Since the Lp [a] lipoprotein contains one mole of apo [a]
disulfide linked to one molecule of ApoB [33], it is possi-
ble to calculate the amount of Lp [a] from the amount of
measured apo [a]. The ApoB, not linked to apo [a] in Lp
[a], is assumed to be present in LDL. LDL is small enough
to penetrate the intimal lining and accumulate in the
subintimal space. Since VLDL is too large to accumulate in
this space and become integrated into an atherosclerotic
lesion, little if any of the ApoB present in these lesions can
be attributed to VLDL. Thus, apo [a] and ApoB quantified
together make it possible to estimate the amount of Lp [a]
and LDL present in the atherosclerotic plaque.
In the carotid arteries, atherosclerotic plaque occurs pre-
dominantly at the bifurcation (B), but also at the internal
(I) and common (C) segments. The external (E) segments
are usually negative for plaque. Previously, ELISA has
been shown to be an effective method for profiling the
above proteins in atherosclerotic tissue samples [34].
LMA technology was used for verification of the presence
of and quantification of these protein markers from the
different segments (with and without plaque) of the
carotid artery samples from 15 different patients (sam-
ples-1014, 1023, 1042, 1098, 1103, 1117, 862, 865, 893,
989, 900, 904, 912, 935 and 979). Lysates were prepared
from 3–4 different segments of an endarterectomy speci-
men resected from the carotid artery for each patient (total
of 52 samples). Serial dilutions of purified Lp(a) (4 pico-
grams to 500 picograms) and LDL (20 picograms to 3
nanograms) were printed to prepare standard curves (sup-
plementary data available) for estimating the amount of
these proteins in the different samples. Each sample was
printed in a dilution series of 5 steps and the printed lysate
amount range was about 120 picograms to 180 nano-
grams. Two arrays each were probed with antibodies for β-
actin, apo [a] and Apo B. Each dilution of each sample was
printed in duplicate on each array resulting in 4 data-
points per dilution per sample. Two arrays processed in
the absence of a primary antibody did not generate dis-
cernable signals. The amount of signal generated in the
arrays probed with apo [a] and Apo B antibodies were
used to estimate the amount of the two proteins markers
in the different sections for each patient with the help of
the standard plots. The specificity of the antibodies for
detection of apo [a] and Apo B has previously been dem-
onstrated and published [34,35].
Cytoskeletal proteins such as β-actin may be differentially
regulated during atherogenesis we determined its stability
in these cases to establish β-actin as a viable control. In
order to detect any variation in β-actin levels, the levels of
β-actin in the different atherosclerotic samples were deter-
mined. The data for 2 patients (samples- 1103 and 898) is
shown in figure 10. The average β-actin levels of the avail-
able samples from the different sections (C, B, I, E) are
shown for each patient. No samples were available for seg-
ment E for patients 898. The data show no significant var-
iation in the β-actin levels thus establishing this protein as
a stable control in these samples valid for use as a means
of normalizing the data. Similar data were generated for
other patient samples.
In order to validate the data generated, aliquots of the
same lysates (100 nanograms to 1 microgram) were used
for verification of the presence and quantification of these
proteins by ELISA, using the same set of antibodies. Stand-
ard plots were generated for ELISA (supplementary data
available) using purified Lp(a) (1 nanogram to 10 nano-
grams) and LDL (10 nanograms to 140 nanograms) and
used to estimate the amounts of these proteins present in
the patient samples. Figures 11 (apo [a]) and 13 (Apo B)
shows statistical correlation of the estimated protein
amounts obtained using LMA and ELISA for the two pro-
tein markers. The correlations of the estimated protein
amounts were highly significant with the r2 ≥ 0.98 (p ≤
0.001) for apo [a] and r2 ≥ 0.94 (p ≤ 0.001) for apo B. Fig-
ures 12 (apo [a]) and 14 (Apo B) show comparative histo-
gram plots for the estimated protein amounts in each
section of each patient sample included in this study. The
protein profiles for both proteins across the different sec-
tions varied between patients but were similar for LMA
and ELISA for all the samples.
Table 3: Summary of data statistics for LMA where printed lysate amount ranged from 0.006 to 6.66 pg.
1XPBS 0.006 0.06 0.66 6.66 (pg)
MEAN 334.50 333.67 344.78 2358.10 8443.57
SD 33.44 19.87 19.34 115.03 279.16
CV (%) 10.00 5.95 5.61 4.88 3.31Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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Discussion
Currently used methods for protein marker detection are
based on classical immunological methods like ELISA
that are not well-suited for high-throughput protein
marker detection of human clinical tissue samples, where
sample amounts are limiting, such as laser-capture micro-
dissected sample or fine needle aspirate samples, due to
the relatively large amount of sample required for the test.
Microarrays offer a means of verification of the presence
of protein markers in a high-throughput manner, typically
in the order of thousands of samples in a single experi-
ment, using much lower amount of sample than required
for ELISA. We have systematically evaluated and opti-
mized LMA for reproducibility in printing, linearity of the
binding, labeling and detection steps and high sensitivity.
The data presented here establish LMA as a potentially
powerful technology for verification of the presence and
quantification of known protein markers. This is the first
comparative study of data generated by LMA and ELISA,
showing a high correlation between the two data sets. The
LMA reduces the amount of lysate sample required by as
much as 1000-fold (nanogram versus picogram amounts)
compared to ELISA. Our data showed a correlation coeffi-
cient, r2 ≥ 0.98 (p ≤ 0.001) for apo [a] (figure 11) and r2 ≥
0.94 (p ≤ 0.001) for apo B (figure 13), between LMA and
ELISA data.
In very few cases the estimated protein amounts by LMA
and ELISA were significantly different. We believe this
may be due to the calcified nature of the carotid endarter-
ectomy samples, which may alter the viscosity of the sam-
ple and thus may interfere with microarray printing. The
presence of calcium in the samples, combined with the
solid-pin printing technology (that is very sensitive to the
level of viscosity of the sample) of microarrayer used for
this study, might make it difficult for the calcified samples
to be dispensed in a precise manner.
LMA offers an easy means of verification of the presence
of protein markers in a high-throughput manner. The for-
mat of LMA, where the lysate is immobilized on the sur-
face and probed with an antibody, enables high-
throughput, and also reduces the amount of sample
required since the lysate is not the limiting factor in the
binding experiments. In LMA, the amount of antibody in
solution exceeds the amount of lysate on the surface, and
hence, the signals from binding are a true reflection of the
amount of protein marker in the lysate. This is crucial to
the comparison of protein markers across samples.
LMA with serially diluted purified proteins are used to
prepare standard curves that can then enable quantifica-
tion of the proteins of interest in the samples. In LMA,
lysate samples are arrayed in a serial dilution thus yielding
at least one or more data points in the dynamic range of
the standard curve for the specific protein-antibody pair
tested.
The sensitivity of detecting the presence of protein
biomarker on LMA is greatly dependent on the signal
detection and amplification method employed. In most
of the studies performed using LMA so far an enzyme-
mediated deposition of biotin-tyramide conjugates at the
site of antibody binding has been used [36]. Although a
sensitivity in the femtogram range has been achieved
using this technology [21], it suffers from saturation at
spots in LMA containing high amounts of the protein of
interest, due to the inability to control the enzymatic reac-
tion [28]. We have demonstrated detection of β-actin pro-
tein from human plasma samples from 600 femtograms
(10-15 gram) of protein lysate using a non-enzymatic sig-
Specificity of p53 antibody Figure 4
Specificity of p53 antibody. Ten micrograms of extracts from 
bacteria over-expressing p53 protein (lane 1) and F9 cell 
lysates (30 µg; lane 2) were analyzed for specificity of the p53 
antibody and expression of p53 by Western blot analysis.
12 M ( k D )
-202
-134
-83
-41
-31
p53Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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nal detection method. Since β-actin is an abundant pro-
tein, we expect the LMA sensitivity for detection of less
abundant proteins to be not as high.
The value and application of LMA is best understood in
studies involving large clinical trials. In such clinical trials,
the presence and the level of protein biomarkers (up to
10) in a group of patients (100–1000 or more) may need
to be determined. The number of proteins is too small for
an antibody array, and the throughput of the number of
samples processed using antibody array is one patient
sample at a time. If antibody arrays are used for this study,
100–1000 or more arrays will be required (one array per
patient sample) whereas with LMA this study can be com-
pleted with 10 arrays with all patient samples arrayed on every
single array and probing with one antibody per array. LMA
would also be a useful technology to use when a large
number of archived samples (thousands) need to be inter-
rogated for a predefined set of protein markers.
Using ELISA, the amount of starting material (lysates)
required is at least 10 times higher than LMA and the
throughput of number of samples processed using ELISA
is only 96 per plate (8–200 samples per experiment using
SELDI-TOF MS). Using LMA, up to 4000 patient samples
can be assayed for the detection of a single protein, simul-
taneously in a single experiment, using simple means of
arraying, hybridization, and imaging, while maintaining
quality controls at each step. Since the amount of sample
required per spot is only a few picograms, many proteins
can be estimated (albeit one at a time) using LMA. Thus,
LMA offer a faster, easier and cheaper (single slide in LMA
versus many slides in antibody arrays) method to study
for large clinical trials.
Reproducibility in signal detection on LMA Figure 5
Reproducibility in signal detection on LMA. Serially diluted lysates (5.0 to 0.625 ng) prepared from human plasma sample were 
printed and probed for detection of β-actin in the presence (top 2 arrays) or absence of the primary antibody (bottom array).Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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One essential requirement for the application of LMA as a
high-throughput protein biomarker tool is to be able to
process and generate protein lysates from patient samples
in an equally high-throughput manner. This can be
achieved by minimal customization of any of the several
liquid-handling robotic set-ups commercially available
today. The protocols adopted for lysate generation will be
dependent on the source of the samples, such as, serum,
biopsies etc. With current capacity of robotics hundreds of
samples could be lysed directly in microtitre plates and
prepared for printing LMA, which can then serve as input
plates for a printing robot, thus requiring minimal sample
handling.
Conclusion
We have demonstrated the use and applicability of lysate
microarray technology for detection and quantification of
pre-determined protein markers. The high sensitivity
(reduces amount of input sample required) and miniatur-
ized format (increases the number of samples assayed on
a single slide) of LMA technology, makes it suitable for
studies such as large clinical trials where thousands of
samples (available in limited quantities) may need to be
interrogated for the expression level of a defined set of
protein markers. LMA can be used for estimating the
amount of specific proteins present in these samples by
generating standard plots prepared using corresponding
purified proteins arrayed on the LMA. The comparative
data analysis of LMA and ELISA data show that the data
were highly correlative (in over 90% of the samples) indi-
cating that LMA can potentially be used as a diagnostic
tool for verification of the presence and quantification of
specific protein markers in clinical samples where the
sample amounts are limiting.
Methods
Purified proteins, antibodies, cell culture and patient 
samples
Purified p53 protein (sc-4246, human) and p53 (C-19,
goat polyclonal), were purchased from Santa Cruz Tech-
nologies (Santa Cruz, CA). The antibody for β-actin (AC-
15, monoclonal) was purchased from Sigma-Aldrich (St.
Louis, MO). Polyclonal antibodies for apo [a] and Apo B
were raised in goat and purified as described previously
[34,35]. Biotinylated secondary antibodies were pur-
chased from Vector Laboratories (Burlingame, CA).
F9 cells were cultured in Dulbecco's Modified Essential
medium (Invitrogen Life Technologies, Carlsbad, CA)
supplemented with 10% Fetal Bovine Serum. All cells
were grown to 80% confluency in 10 cm plates at 37°C.
Cells were washed twice in 1XPBS and cell pellets were
stored at -70°C until further use. Lysates from bacteria
over expressing p53 protein were a gift from Dr. Guiller-
mina Lozano [37]. Normal human plasma and surgical
tissue samples were obtained under a protocol approved
Specificity of β-actin antibody Figure 7
Specificity of β-actin antibody. Human plasma samples (lanes 
1 and 2) were used to determine the specificity of the anti-
body for β-actin by Western blot analysis.
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Correlation of signal intensity to lysate amount printed on  LMA Figure 6
Correlation of signal intensity to lysate amount printed on 
LMA. Lysate amount printed on LMA (5.0 to 0.625 ng/spot in 
Figure 5) was plotted against signal intensity
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by the Human Research Committee of Baylor College of
Medicine, Houston, TX.
Tissue processing
Tissue samples were obtained at endarterectomy of
atherosclerotic carotid arteries from patients enrolled in a
cardiovascular study at the Methodist Hospital (Houston,
TX) and stored immediately after surgery in PBS contain-
ing 50% glycerol at -20°C until imaged or analyzed. Slits
in the carotid artery tissue created at surgery were closed
by annealing opposing sides with superglue so as to
recover the original spatial relationships within the tissue.
The tissue was x-rayed using a FAXITRON analyzer to
identify areas of calcification and guide subsequent dis-
section. After magnetic resonance imaging (MRI), the tis-
sue was marked with a thin line of India ink along the
long axis. Transverse segments 3 mm long (corresponding
to the MRI slice thickness) were cut with a scalpel, starting
at the bifurcation and extending into the common, inter-
nal and external areas of the arteries. Segments were inked
on the proximal end to preserve the correct end-to-end
relationship. Segments (100 mg) were then transferred to
15 ml plastic tubes containing 3 ml of extraction buffer
(50 mM Hepes, pH7.4, 150 mM NaCl, 1 mM EGTA, 10
mM sodium pyrophosphate, 100 mM NaF, 1.5 mM
MgCl2, 10% Glycerol, 1% Triton X-100, pH 7.4) then
homogenized at 10°C for 10–20 sec (Polytron, Brink-
mann). The homogenate was centrifuged at 3500 rpm for
30 min and the supernatant decanted for storage at -80°C
until analyzed.
Cell Lysate Preparation
The pellets from F9 cells and patient samples were sus-
pended in extraction buffer (as above) containing 0.5X
Sensitivity of LMA Figure 8
Sensitivity of LMA. Two arrays were printed using serial dilutions (6.66 to 0.006 pg) of human plasma sample and probed for β-
actin.Proteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
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protease inhibitor cocktail (Roche Diagnostics, Man-
nheim, Germany). The cell lysate was incubated on ice for
30 min followed by centrifugation at 4°C, 14,000 rpm for
10 min. The supernatant was transferred to a fresh tube.
The protein concentration was measured using the Brad-
ford assay (Bio-Rad, Hercules, CA) as per manufacturer's
instructions. The proteins were solubilized by addition of
one-third volume 4X SDS buffer (0.25 M Tris.HCl, pH 6.8,
40% glycerol, 8% SDS and 10% β-mercaptoethanol) and
denatured at 94°C for 5 min. Aliquots of extracts contain-
ing denatured proteins were stored at -70°C. Plasma sam-
ples and purified proteins were directly denatured in 4X
SDS buffer as above.
Array manufacture and Processing
The lysates were serially diluted in 1 X phosphate-buffered
saline (PBS, Invitrogen, Carlsbad, CA), to desired concen-
trations and transferred to a 384 well plate (20 µl/well;
Fisher Scientific, Pittsburg, PA). The lysates were printed
onto membrane-coated glass slides (FAST slides, Sch-
leicher & Schuell Bioscience, Keene, NH) using the Flexys
robot (Genomic solutions, Ann Arbor, MI). Flexys is a
solid pin robot with an estimated printed amount of 1 nl
per spot (Genomics Solutions, Inc. Irvine, CA). All sam-
ples were printed in a dilution series of 4 or more steps.
Two or more replicates of each sample concentration were
printed per array and each experiment set included 2 or
more arrays (2 or more slides). The arrays were stored at
4°C until further use.
Non-specific binding sites on the arrays were blocked by
addition of 10 ml of 1 X Wash/Block buffer (Fast Pak2
protein array kit, Schleicher & Schuell Bioscience, Keene,
NH) and incubation with gentle rocking, for 2 h at room
temperature. The excess buffer was drained off without
allowing the arrays to dry. This was followed by binding
with 50 µl of primary antibody at a concentration of 10
ng/µl in 1XPBS containing 0.5% Tween-20 (Sigma-
Aldrich, St. Louis, MO) and 5% bovine serum albumin
(BSA, Sigma-Aldrich, St. Louis, MO). The array was cov-
ered with a cover slip and incubated in a humid chamber
Comparison of apo [a] protein estimated by LMA and ELISA Figure 11
Comparison of apo [a] protein estimated by LMA and ELISA. 
Statistical correlation between the amount of apo [a] esti-
mated (µg/ml) by LMA and ELISA.
apo[a]
r2 > 0.98
p<0.001
LMA
0 5 10 15 20 25 30 35
E
L
I
S
A
0
5
10
15
20
25
30
35
Correlation of signal intensity to lysate amount printed on  LMA Figure 9
Correlation of signal intensity to lysate amount printed on 
LMA. Lysate amount printed on LMA (6.66 to 0.006 pg/spot 
in Figure 8) was plotted against signal intensity
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Detection of β-actin protein levels in atherosclerotic samples  by LMA Figure 10
Detection of β-actin protein levels in atherosclerotic samples 
by LMA. Lysates prepared from sections C, B, E and I were 
analyzed for expression of β-actin by LMA. The average sig-
nal intensity for the different sections for 2 patients (samples-
1103 and 898) is shown.
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overnight (15–16 hr) at 4°C. Slides were rinsed in 1 X
Wash/Block buffer for 5 min with gentle rocking at room
temperature to remove the cover slip. Each slide was care-
fully removed from the Wash/Block buffer letting the
excess buffer drain off without allowing the arrays to dry.
Next, 50 µl buffer (50 mM Tris pH 7.5, 1.5 M NaCl, 0.1%
Tween-20) containing biotinylated secondary antibody
(Vector Laboratories, Burlingame, CA) at a concentration
of 5 ng/µl was added to the arrays and a cover slip was
placed on the arrays. The arrays were incubated in a
humid chamber at room temperature for 1 h.
Slides were rinsed in 1 X Wash/Block buffer for 5 min with
gentle rocking at room temperature to remove the cover-
slip. Slides were removed from the wash/Block buffer let-
ting the excess buffer drain off without allowing the arrays
to dry. Cyanine 3/Cyanine 5 (Cy3/Cy5)-labeled streptavi-
din dyes (Amersham Biosciences, Piscataway, NJ) were
reconstituted in water to a stock of 1 mg/ml. Next, 50 µl
of the Cy3/Cy5-labeled streptavidin (1:3 (v/v) in 1XPBS)
was added to the array and covered with a cover slip. The
arrays were incubated in a dark humid chamber at room
temperature for 1 h. Slides were rinsed in 1 X Wash/Block
buffer for 5 min with gentle rocking at room temperature
to remove the cover slip. The slides were removed from
the wash tray, placed in a 50 ml tube and dried by centrif-
ugation at 1.5 rcf for 90 sec in a clinical centrifuge.
Monofunctional NHS-esters forms (for labeling com-
pounds containing free amino groups) of Cy3 and Cy5
monoreactive dyes (Amersham Biosciences, Piscataway,
NJ) were used to label protein lysates. 100 µl of 0.1 M
sodium carbonate buffer (pH 8.0) was added to each of
the Cy3 and Cy5 monoreactive dyes (to yield a stock of 10
Comparison of apo [a] protein estimated by LMA and ELISA Figure 12
Comparison of apo [a] protein estimated by LMA and ELISA. Comparative histogram plot (x-axis: patient sample; y-axis: pro-
tein amount in µg/ml) for the estimated protein amounts by LMA and ELISA for all samples are shown.
0
5
10
15
20
25
30
35
1
0
1
4
c
1
0
1
4
e
1
0
1
4
i
1
0
2
3
b
1
0
2
3
c
1
0
2
3
e
1
0
2
3
i
1
0
4
2
c
1
0
4
2
e
1
0
4
2
i
1
0
9
8
c
1
0
9
8
i
1
1
0
9
8
i
2
1
1
0
3
b
1
1
0
3
c
1
1
0
3
e
1
1
0
3
i
1
1
1
7
b
1
1
1
7
c
1
1
1
7
e
1
1
1
7
i
8
6
2
b
8
6
2
c
8
6
2
e
8
6
2
i
8
6
5
c
8
6
5
e
8
6
5
i
8
9
3
c
8
9
3
e
8
9
3
i
8
9
8
b
8
9
8
c
8
9
8
i
9
0
0
c
9
0
0
e
9
0
0
i
9
0
4
c
9
0
4
e
9
0
4
i
9
1
2
c
9
1
2
e
9
1
2
i
9
3
5
b
9
3
5
c
9
3
5
e
9
3
5
i
9
7
9
b
9
7
9
c
9
7
9
e
9
7
9
i
LMA
ELISAProteome Science 2005, 3:9 http://www.proteomesci.com/content/3/1/9
Page 13 of 16
(page number not for citation purposes)
mg/ml) and 25 µl of the dye (Cy3 or Cy5) was added to
different amounts of protein/lysate to be labeled. The
final volume of the solution was adjusted to 35 µl using
0.1 M Sodium carbonate buffer (pH 8.0). The protein-dye
mixture was incubated at 4°C for 1 hour and agitated gen-
tly every 10 min. This was followed by the addition of 3.5
µl of 1 M Tris.HCl (pH 8.0) and 1XPBS to give a final vol-
ume of 500 µl. The protein solution was concentrated by
passing it through a micro concentrator spin column
(Amicon-Microcon YM-10 column, Millipore, Billerica,
MA) and centrifugation at 14000 rcf for 25 min, reducing
the volume to 30 µl. This step also facilitated the removal
of unincorporated dye molecules from the labeled protein
solution.
ELISA
ELISA was performed as described by us previously [29].
Briefly, 100 µl of serially diluted purified Lp(a) or LDL
(starting with a stock of 1 mg protein/ml in PBS, pH7.2)
were added to 96-well microtitre plates (Dynatech Labs,
Alexandria, VA) and incubated for 2 h at room tempera-
ture (RT). Two wells were left uncoated to serve as con-
trols. The plates were washed successively with PBS-BSA
(PBS containing 0.5% BSA) and PBS. Plates were incu-
bated with PBS-BSA for 2 h at RT, then overnight at 4°C.
Appropriate dilutions (prepared in PBS-BSA) of homgen-
ate supernanants prepared from atherosclerotic tissue
samples were mixed with the antibody against apo [a] or
Apo B (1: 5000 dilution) and added to the plates. Anti-
body diluted in PBS-BSA was added to the uncoated wells.
Plates were incubated for 2 h at RT, then overnight at 4°C.
Plates were washed as before and incubated with a perox-
idase-conjugated secondary antibody that is immunoreac-
tive against the IgG species (anti-IgG-HRP; 1: 2500
dilution; Cappel labs, Cochranville, PA), followed by
incubation at RT for 2 h and washing. Substrate solution
was prepared by dissolving 10 mg of o-phenylenediamine
in 25 ml of phosphate-citrate buffer (24.3 mM citrate,
51.2 mM phosphate, pH 5.0) containing 10 µl of 30%
H2O2. Next 160 µl of substrate solution was added to each
well, the reaction carried out for 30–60 min at RT and
then quenched by addition of 40 µl of 2.5 N sulfuric acid.
Absorbance at 492 nm was measured using a plate reader
(Titertek Multiskan Plus MKII microtitre plate reader,
Flow Laboratories). The absorbance values of samples
were equated to Lp [a] or LDL protein using standard
curves generated with purified lipoproteins, whose pro-
tein content had been previously measured by Bradford
assay (Bio-Rad, Hercules, CA).
Western Blot Analysis
Thirty micrograms of denatured lysates were subjected to
10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis. After electrophoresis, Western blotting was per-
formed using Hybond nitrocellulose membranes
(Amersham, Piscataway, NJ) as per manufacturer's proto-
cols. After protein transfer, the membranes were washed
and blocked in 1XPBS buffer containing 0.3% Tween 20
and 5% milk for 15 min at RT and incubated with respec-
tive primary antibody (at 1:1000 dilution in 1XPBS con-
taining 0.3% Tween 20 and 5% BSA) overnight at 4°C on
a shaker. The membranes were washed 3 times with PBST
(1XPBS containing 0.3% Tween 20) for 10 min at RT each
time and subsequently incubated with the respective sec-
ondary antibody (1:1000–3000 dilution of HRP-conju-
gated anti-rabbit IgG, anti-mouse IgG or anti-rabbit IgG in
1XPBS containing 0.3% Tween 20 and 5% BSA; Amer-
sham Biosciences, Piscataway, NJ) for 1 h at RT with shak-
ing. The blots were washed with PBST as before and the
protein bands were detected using ECL Plus Western Blot-
ting Detection Reagents (Amersham, Piscataway, NJ).
Imaging and Data Analysis
All microarrays were imaged at 10µ resolution using a
dual laser-scanner (GenePix 4000; Axon Instruments,
Union City, CA) to capture fluorescence intensity signals
generated for Cy3 at 532 nm or Cy5 at 635 nm. Image
acquisition and quantification were performed using
GenePix Pro 4.1 (Axon Instruments, Union City, CA). The
signal intensity at each spot was determined by subtract-
ing the median intensity of the background pixels from
the mean intensity of the foreground pixels. These back-
ground-corrected intensity values were truncated by
replacing negative or zero values by the threshold value of
1.
For some analyses, the signal intensities were transformed
by computing the logarithm (base two). For replicates of
Comparison of Apo B protein estimated by LMA and ELISA Figure 13
Comparison of Apo B protein estimated by LMA and ELISA. 
Statistical correlation between the amount of Apo B esti-
mated (µg/ml) by LMA and ELISA.
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each sample spotted on each array, mean, standard devia-
tion (SD) and coefficient of variance (CV) were calculated.
To analyze the data for determining the performance of
different binding reactions, we fitted a Generalized Linear
Mixed Model with common slope for log concentration,
fixed effect for the specific binding step with Cy3 as the
reference group and random effect for array. The response
was log intensity. Since the intensity was base two loga-
rithmic transformed, two to the difference power of the
intercepts between the different reactions was the ratio of
the intensities, which represented the relative amount of
the signal for the specific reaction. We used Cy3-streptavi-
din as the reference and calculated the ratios of other reac-
tion signals based on it. This resulted in the relative signal
for the specific signal as compared to Cy3.
For the comparing the data generated using ELISA and
LMA, same set of protein lysates were used for LMA and
ELISA experiments. Standard plots were generated using
purified proteins for both technologies. The standard
plots were used to estimate the amount of the specific pro-
teins in each sample. SigmaPlot (Statistical Solutions,
Saugus, MA) was used for determining the correlation
between the protein amounts estimated in each sample by
LMA and ELISA experiments.
List of Abbreviations
LMA (lysate microarrays), ELISA (enzyme-linked immu-
nosorbent assay), apo [a] (apolipoprotein [a]), LDL (low
density lipoprotein), Apo B (apolipoprotein B)
Comparison of Apo B protein estimated by LMA and ELISA Figure 14
Comparison of Apo B protein estimated by LMA and ELISA. Comparative histogram plot (x-axis: patient sample; y-axis: protein 
amount in µg/ml) for the estimated protein amounts by LMA and ELISA for all samples are shown.
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